CymaBay Therapeutics
7999 Gateway Blvd.
Suite 130
Newark
California
94560
United States
Tel: 510-293-8800
Website: http://www.cymabay.com/
Email: info@cymabay.com
About CymaBay Therapeutics
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).
172 articles about CymaBay Therapeutics
-
CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
8/24/2022
CymaBay Therapeutics, Inc. today announced that management will participate in a mini symposium on primary biliary cholangitis (PBC) hosted by B. Riley Securities on Wednesday, August 24.
-
CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update
8/11/2022
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced corporate updates and financial results for the second quarter ended June 30, 2022.
-
With Monkeypox, COVID-19, Long COVID symptoms and persistent diseases like cancer and Alzheimer's, the world is dealing with a lot right now. Here's a look at the latest in clinical trial news.
-
CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022
8/4/2022
CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update.
-
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis
8/1/2022
CymaBay Therapeutics, Inc. today announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis (PBC).
-
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
6/22/2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced encouraging seladelpar data in patients with primary biliary cholangitis (PBC) that are being presented at The International Liver Congress™ 2022.
-
CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
5/23/2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from new analyses of clinical studies of seladelpar were presented during Digestive Disease Week® (DDW) .
-
CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/12/2022
CymaBay Therapeutics, Inc. announced corporate updates and financial results for the first quarter ended March 31, 2022.
-
CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022Seladelpar Phase 2 Study Selected for DDW Presidential Plenary Session
5/11/2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple Phase 2 and Phase 3 study presentations on seladelpar, the first delpar currently in development for the treatment of PBC, will be delivered during Digestive Disease Week® (DDW) May 21 – 24.
-
CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022
5/5/2022
CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, May 12, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2022 and to provide a business update.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
4/4/2022
CymaBay Therapeutics, Inc. today announced that results from the Phase 2, 52-week study of seladelpar in patients with primary biliary cholangitis (PBC) have been published in the Journal of Hepatology.
-
CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update
3/17/2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth quarter and fiscal year ended December 31, 2021.
-
CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors
3/17/2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors.
-
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022
3/10/2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 17, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2021 and to provide a business update.
-
CymaBay Therapeutics to Present at Upcoming Investor Conferences - Feb 10, 2022
2/10/2022
CymaBay Therapeutics, Inc. announced that management will participate in two virtual investor conferences including the 11th Annual SVB Leerink Global Healthcare Conference taking place February 14-18, 2022 and Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-16, 2022.
-
The holds were lifted by the FDA in July of 2020, but the company’s timeline had been severely set back by the miscalculation.
-
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
11/18/2021
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.
-
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
11/17/2021
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
-
CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC
11/15/2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that results of analyses from two clinical studies of seladelpar were delivered during The Liver Meeting Digital Experience™ 2021 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD).